Bringing vaccines to chronic disease


Bringing Vaccines
to chronic disease


Bringing Vaccines
to chronic disease

Supervisory Board

Michael MotschmannMichael Motschmann, Chairman

Michael has been an entrepreneur for over 20 years. In 2004, Michael co-founded MIG Verwaltungs-AG, and as a member of the Board of Management he is Head of the participations division. MIG AG is a management company for various VC funds which are financed by private investors and which invest in companies in Germany and Austria, mainly in the life science and high-tech fields. Major biotech investments include BioNTech, Immatics and AFFiRiS. Recent exits include the €200m disposal of Suppremol to Baxalta and the €422m disposal of Ganymed Pharmaceuticals to Astellas.

Helmut W. Jeggle, MBA, Vice Chairman

Helmut is Managing Director of ATHOS Service GmbH in Munich. Helmut has been responsible for building ATHOS/Santo’s extensive portfolio of biotechnology companies. He has been instrumental in recent exit transactions such as the sale of Ganymed Pharmaceuticals to Astellas and the €200m disposal of Suppremol to Baxalta. Prior to joining ATHOS/Santo Helmut held various positions in finance at Hexal and at Sandoz.

Prof. Dr. Christoph Huber

Prof. Dr. Christoph Huber is professor emeritus at the Johannes-Gutenberg University Mainz, former head of the Department of Hematology and Oncology at the Mainz University Medical Center and an international leader in the field of immuno-oncology. He chairs Europe´s Association for Cancer Immunotherapy (CIMT), is board member of the Ci3 Cluster of Individualized ImmunIntervention e.V at the Rhine-Main Metropolitan Area and senior advisor to international pharmaceutical companies, science-driven SMEs and Big Science Institutions. Prof. Huber is also co-founder of BioNTech AG and of Ganymed Pharmaceuticals AG.

Noel BarrettNoel Barrett, PhD

Noel Barrett is a distinguished business leader in the field of vaccines. He has more than 30 years’ experience in the vaccine and biologics industry with management responsibilities covering the complete development process required to bring vaccine products to the market. In his prior position as Vice President Global R&D Vaccines at Baxter Healthcare he led the development and licensure of Baxter’s FSME Tick-borne encephalitis vaccine, Meningococcus C, cell-culture derived H5N1, H1N1 and seasonal influenza vaccines (Preflucel).
His contribution to the Baxter scientific community was recognised with the title of Baxter Distinguished Scientist, the most prestigious scientific recognition within the company and the Baxter Bioscience President’s Leadership Award.

Claudia JunoClaudia Juno

Claudia Juno studied biomedical analytics at the Vienna General Hospital and has been employed at AFFiRiS AG since 2008. She has gained longstanding laboratory experience in university and industry settings from the Max F. Perutz Laboratories, the University College London and Baxter BioScience among others. At AFFiRiS Ms. Juno has worked on several projects in Parkinson’s disease and CETP. Since 2012, she is part of the PCSK9 project team. Ms. Juno has been appointed by the works council as a delegate to the supervisory.

Marie Le BrasMarie Le Bras

Mag. Marie Le Bras studied human biology at the University of Vienna and has been employed at AFFiRiS AG since 2009. She has gained experience in research laboratories of the Vienna General Hospital, the Royal Free Hospital in London and the Children’s Cancer Research Institute of Vienna. At AFFiRiS Ms. Le Bras has worked on CETP and Osteopontin projects. Since 2012, she is part of the PCSK9 project team. Ms. Le Bras has been appointed by the works council as a delegate to the supervisory board.

Kommentare sind geschlossen.